39.50
Schlusskurs vom Vortag:
$39.60
Offen:
$39.78
24-Stunden-Volumen:
2.47M
Relative Volume:
0.98
Marktkapitalisierung:
$4.67B
Einnahmen:
$1.29B
Nettoeinkommen (Verlust:
$251.00M
KGV:
20.01
EPS:
1.9744
Netto-Cashflow:
$-193.86M
1W Leistung:
+4.89%
1M Leistung:
+23.67%
6M Leistung:
+26.04%
1J Leistung:
+259.74%
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Firmenname
Indivior Pharmaceuticals Inc
Sektor
Telefon
804-379-1090
Adresse
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
INDV
Indivior Pharmaceuticals Inc
|
39.50 | 4.67B | 1.29B | 251.00M | -193.86M | 1.9744 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.46 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.73 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.11 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
82.83 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
UTHR
United Therapeutics Corp
|
564.94 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-22 | Fortgesetzt | Jefferies | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-23 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-03 | Eingeleitet | Craig Hallum | Buy |
| 2023-07-13 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Indivior Pharmaceuticals Inc Aktie (INDV) Neueste Nachrichten
Indivior launches $175M accelerated share buyback - MSN
Indivior Pharmaceuticals Inc. (INDV) Q1 earnings and revenues beat estimates - MSN
Indivior Pharmaceuticals Inc. (INDV) is a great momentum stock: Should you buy? - MSN
Indivior Pharmaceuticals Inc. (INDV) upgraded to strong buy: Here's what you should know - MSN
Zacks.com featured highlights include The Vita Coco Company, Indivior Pharmaceuticals and Marathon Petroleum - Yahoo Finance
Wall Street analysts predict a 27.76% upside in Indivior Pharmaceuticals Inc. (INDV): Here's what you should know - MSN
New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations - Quantisnow
Why Indivior Pharmaceuticals (INDV) Is Up 9.8% After Raising 2026 Revenue Guidance And Earnings - Sahm
Indivior Pharmaceuticals Inc. (INDV) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Here's why momentum in Indivior Pharmaceuticals Inc. (INDV) should keep going - MSN
Wall Street Analysts Predict a 27.76% Upside in Indivior Pharmaceuticals Inc. (INDV): Here's What You Should Know - Yahoo Finance
Best Momentum Stock to Buy for May 5th - Yahoo Finance
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News - Sahm
Indivior Announces $175 Million Accelerated Share Repurchase Agreement Under Existing Authorization - Minichart
Indivior Announces $175 Million Accelerated Share Repurchase - TipRanks
Indivior starts $175M buyback with 3.7M shares due upfront - Stock Titan
Indivior enters $175M accelerated share repurchase, receives 3.72M initial shares - TradingView
Indivior (INDV) 10K Form and Latest SEC Filings 2026 - MarketBeat
Indivior Earnings Call Highlights SUBLOCADE-Fueled Momentum - The Globe and Mail
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After A 214% One-Year Surge? - Yahoo Finance
Is It Too Late To Consider Indivior Pharmaceuticals (INDV) After Its 214% One-Year Surge? - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Bausch + Lomb Corporation (BLCO) and Indivior (INDV) - The Globe and Mail
Indivior Pharmaceuticals Q1 2026 Deep Dive: EPS Beats by 43.3%, Revenue Up 19% - AlphaStreet
Indivior (INDV) Q1 2026 Earnings Transcript - AOL.com
Here's Why Momentum in Indivior Pharmaceuticals Inc. (INDV) Should Keep going - Yahoo Finance
Indivior PLC Q1 2026 Earnings Call Summary - Yahoo Finance
Indivior Posts Strong Q1 Results, Raises 2026 Outlook - The Globe and Mail
Indivior Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:INDV) 2026-04-30 - Seeking Alpha
Indivior Pharmaceuticals Crushes Q1 2026 Profit Estimates by 43.3% - AlphaStreet
Indivior Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Indivior Q1 2026 Earnings Call Transcript - MarketBeat
Indivior (INDV) Raises FY26 Guidance on Strong SUBLOCADE Performance - GuruFocus
Indivior (INDV) Reports Strong Q1 Revenue Growth - GuruFocus
Is Indivior (INDV) 56.5% Overvalued After Q1 2026? Revenue $317M - GuruFocus
Indivior Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Indivior Q1 2026 sees strong results, stock surges - Investing.com Canada
Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge - ChartMill
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q1 Revenue $317.0M, vs. FactSet Est of $272.8M - marketscreener.com
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.96 per Share, vs. FactSet Est of $0.66 - marketscreener.com
Indivior Pharmaceuticals Q1 revenue rises 19%, beats estimates - TradingView
Indivior (NASDAQ: INDV) lifts 2026 guidance on SUBLOCADE growth and margin expansion - Stock Titan
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance - Moomoo
Finanzdaten der Indivior Pharmaceuticals Inc-Aktie (INDV)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):